Several companies reported their first-quarter 2025 financial results and provided corporate updates. Oklo Inc. reported its first-quarter financial results and business update, with its stock rising 18% following the announcement. The company is advancing on multiple fronts, including initial reactor deployment, isotope business, and a commercial-sized fuel fabrication facility. Oklo has initiated Phase 1 of the pre-application readiness assessment and was selected as one of eight qualified vendors for the Department of Defense's Advanced Nuclear Power for Installations Program (ANPI). Analysts from Citibank and Wedbush maintain a neutral to outperform rating on Oklo, noting its unique build-own-operate model and progress amid anticipated growth in nuclear demand. Several new executive orders are under consideration to expand the U.S. nuclear fleet by 2050 and enhance nuclear procurement by the Department of Defense. Incannex Healthcare Inc. provided a clinical program update on IHL-42X, an oral once-daily treatment for obstructive sleep apnea (OSA). The company completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study, with end-of-study follow-up expected by May 17, 2025, and topline results anticipated in July 2025. Incannex also reported fiscal third-quarter 2025 financial results. Virgin Galactic Holdings, Inc. reported first-quarter 2025 earnings with revenue of $461,000, surpassing estimates of $285,700. The net loss improved to $84.5 million from a $102 million loss year-over-year, and earnings per share (EPS) were -$2.38, better than the estimated -$2.55. The company has $567 million in cash and plans to resume commercial spaceflight ticket sales in the first quarter of 2026, with spaceflights targeted for summer 2026. Virgin Galactic's stock rose 16% in after-hours trading following the earnings release despite a 98.24% decline since its de-SPAC merger. The company is currently pausing commercial spaceflights to develop its Delta Class SpaceShips and plans to increase ticket prices upon resuming sales.